CSIMarket
 
Geron Corp  (GERN)
Other Ticker:  
 
 
Price: $3.3600 $1.61 92.000%
Day's High: $3.49 Week Perf: 49.33 %
Day's Low: $ 3.00 30 Day Perf: 62.32 %
Volume (M): 111,711 52 Wk High: $ 3.74
Volume (M$): $ 375,349 52 Wk Avg: $2.40
Open: $3.00 52 Wk Low: $1.64



 Market Capitalization (Millions $) 1,947
 Shares Outstanding (Millions) 580
 Employees 25
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -175
 Cash Flow (TTM) (Millions $) -30
 Capital Exp. (TTM) (Millions $) 1

Geron Corp
Geron Corporation is a biotech company headquartered in Menlo Park, California, United States. The company focuses on the research and development of therapies to treat cancer and various degenerative disorders. They specialize in anti-telomerase therapy, which is aimed at preventing the uncontrolled multiplication of cells. This therapy targets an enzyme called telomerase, which is responsible for the unending replication of cancerous cells.

The company's flagship product, Imetelstat, is a potent inhibitor of telomerase that has shown promising results in the treatment of blood cancers such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The drug works by disabling telomerase, a key enzyme that allows cancer cells to divide indefinitely. Imetelstat has been shown to prolong survival in patients with MDS and AML, with some patients achieving complete remission.

In addition to Imetelstat, Geron has an active pipeline of drugs in development for the treatment of cancer and degenerative diseases. These include GRN510, a drug that targets breast cancer stem cells, and GRNVAC1, a therapeutic vaccine for cancer.

Geron's research also extends to degenerative diseases such as spinal cord injuries, and it has a drug in development called GRNOPC1 that targets the regeneration of damaged nerve cells in the spinal cord. This therapy aims to replace damaged oligodendrocytes in the spinal cord, which help to protect and insulate nerve cells.

Since its inception in 1990, Geron has raised more than $1 billion in funding for research and development. The company collaborates with various partners from the pharmaceutical industry and academic institutions to advance its products and pursue new therapies.

Overall, Geron Corporation is a pioneering biotech company that continues to drive innovation in the areas of cancer and degenerative disease therapy. Its portfolio of products in development and research collaborations reflect its commitment to finding new treatments for some of the world's most challenging medical conditions.


   Company Address: 919 EAST HILLSDALE BOULEVARD FOSTER CITY 94404 CA
   Company Phone Number: 473-7700   Stock Exchange / Ticker: NASDAQ GERN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Geron Corp

Geron Corp's Disastrous Third Quarter 2023: Revenue Collapse Signals Trouble Ahead


As an avid investor and analyst, I have closely examined the financial results of Geron Corp's third quarter of 2023 earnings season. Though the numbers may raise concerns for some, a deeper analysis reveals positive signs for the future of this biotechnology company.
Firstly, let's address the earnings per share (EPS) figures. Geron Corp has reduced its loss per share from $-0.10 to $-0.08 compared to the same quarter last year. Moreover, the company has shown an improvement in EPS from $-0.09 in the previous financial reporting period. While a loss is never desired, seeing a decline in losses and an upward trend in EPS is a step in the right direction.

Geron Corp

Second Quarter of 2023 Sees Significant Amplification of Diminishing Returns at GERN



Geron Corp, a major player in the pharmaceutical preparations sector, faced a catastrophic second quarter in 2023, as its revenue plunged by a staggering -60.274% to just $0.03 million. This significant decline in revenue has been coupled with a widened shortfall per share, now standing at $-0.09. In stark contrast, the remainder of the sector showed growth, with a 1.81% increase in revenue compared to the same reporting period last year.
Revenue and Earnings Performance:
Geron Corp's second quarter report for 2023 unveils a troubling scenario. While the company struggled to maintain a profitable trajectory, its competitors in the same sector witnessed substantial growth. This discrepancy raises concerns about Geron Corp's ability to effectively navigate the volatile pharmaceutical landscape.

Geron Corp

Geron Corp Makes Strides with EPS Improvement, but Faces Steep Revenue Decline

Geron Corp, the biopharmaceutical company based in California, has seen a notable improvement in its EPS (earnings per share) for the period of January to March 31, 2023. The company achieved a loss per share of $-0.07 compared to $-0.09 a year ago and an EPS increase from $-0.09 per share from the previous quarter.
However, the company's revenue decreased sharply by -82.927 % to $0.02 million from $0.12 million in the same quarter a year ago. Similarly, the revenue tumbled by -79.612 % from $0.10 million sequentially. The revenue decrease is significant and may be attributed to several factors such as economic downturns, increased competition, or changes in consumer behavior.






 

Geron's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com